← All trials
NCT06093841
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2027
- First posted
- Oct 23, 2023
- Last posted
- Oct 25, 2023
- Enrollment
- 46
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Ming Ju Biotechnology Co., Ltd.Lead sponsor
- Soochow UniversityOverall official - principal investigator
- Jiao Tong UniversityOfficial
- Soochow UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.